SmithKline/Glaxo Denavir team approach could work for cold sore cream OTC switch.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE, GLAXO DENAVIR TEAM APPROACH FOR Rx-TO-OTC SWITCH of SmithKline's topical cold sore treatment could be one outcome of the proposed merger between Glaxo Wellcome and SmithKline Beecham. At a September 1996 analysts meeting, SmithKline CEO Jan Leschly said the company would pursue the switch of Denavir immediately upon receiving Rx approval, which was granted by FDA on Sept. 24, 1996, and SmithKline's consumer healthcare products unit markets the Rx product ("The Tan Sheet" Sept. 30, 1996, p. 14). The two companies announced they were in merger talks Jan. 30, signaling the end to discussions between SmithKline Beecham and American Home Products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning